OncoMatch/Clinical Trials/NCT05958719
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Is NCT05958719 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Chidamide and Azacitidine for peripheral t cell lymphoma.
Treatment: Chidamide · Azacitidine · liposomal mitoxantrone · prednisone — This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated angioimmunoblastic T-cell lymphoma (AITL). It's a single-arm study comparing CAMP's safety and efficacy to standard treatments. Younger patients (≤70) receive the full CAMP regimen, while older patients receive a modified version (CAMP-light). Patients are assessed via PET-CT after 4 cycles. Responders (CR/PR) receive consolidation therapy and then maintenance chidamide for 2 years. Eligible patients achieving CR after 4 cycles can get a transplant, while those with PR need 2 more cycles first. Patients with stable or progressive disease after 4 cycles are withdrawn. Progression at any time leads to study discontinuation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
Patients who have previously received chemotherapy
Cannot have received: radiotherapy
Patients who have previously received radiotherapy
Cannot have received: other antitumor therapy
Patients who have previously received...other antitumor therapy
Lab requirements
Blood counts
absolute value of neutrophils (≥1×10^9/l); platelet count (≥75×10^9/l)
Kidney function
serum creatinine (cr) ≤2 uln, or glomerular filtration rate ≥40ml/min
Liver function
serum total bilirubin ≤ 1.5 times uln; ast, alt ≤3 times uln
Cardiac function
lvef value measured by echocardiography ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify